Un arr\u00eat\u00e9 du 17 juillet 2026 abroge, \u00e0 compter du 20 juillet 2026, l\u2019arr\u00eat\u00e9 du 12 f\u00e9vrier 2025 qui rendait obligatoire la d\u00e9livrance \u00e0 l\u2019unit\u00e9 des m\u00e9dicaments \u00e0 base de qu\u00e9tiapine 50 mg \u00e0 lib\u00e9ration prolong\u00e9e (LP), pris en application de l\u2019article L. 5121-33-1 du code de la sant\u00e9 publique. Cette abrogation intervient dans un contexte d\u2019am\u00e9lioration de la disponibilit\u00e9 des m\u00e9dicaments \u00e0 base de qu\u00e9tiapine LP, alors que des tensions d\u2019approvisionnement importantes avaient auparavant affect\u00e9 tous les dosages (50 mg, 300 mg et 400 mg LP), en raison de difficult\u00e9s de production chez le fabricant Pharmathen International, fournisseur de plusieurs laboratoires.<\/p>\n
La recommandation ant\u00e9rieure de l\u2019Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM), permettant aux pharmaciens de substituer, en dernier recours, une pr\u00e9paration magistrale de qu\u00e9tiapine \u00e0 lib\u00e9ration imm\u00e9diate (LI) \u00e0 un m\u00e9dicament \u00e0 base de qu\u00e9tiapine LP indisponible, prend \u00e9galement fin au 20 juillet 2026. \u00c0 partir de cette date, les pharmaciens doivent d\u00e9livrer uniquement le m\u00e9dicament prescrit ; les pr\u00e9parations magistrales de qu\u00e9tiapine LI ne peuvent plus \u00eatre remises qu\u2019en cas de prescription explicite.<\/p>\n
Face aux tensions d\u2019approvisionnement, plusieurs mesures avaient \u00e9t\u00e9 mises en place : contingentement quantitatif des sp\u00e9cialit\u00e9s concern\u00e9es, arr\u00eat des exportations par les grossistes r\u00e9partiteurs, demande aux laboratoires d\u2019identifier des sp\u00e9cialit\u00e9s de qu\u00e9tiapine LI (non commercialis\u00e9es en France) ou LP importables, quelle que soit la dose, et d\u00e9ploiement d\u2019un dispositif de pr\u00e9parations magistrales de qu\u00e9tiapine et de dispensation \u00e0 l\u2019unit\u00e9. L\u2019ANSM a par ailleurs \u00e9mis des recommandations de bon usage afin de limiter l\u2019impact de la p\u00e9nurie : restriction des prescriptions aux seules indications autoris\u00e9es (avec exclusion de l\u2019usage pour l\u2019insomnie), absence d\u2019initiation de nouveaux traitements par qu\u00e9tiapine LP sauf pour les \u00e9pisodes d\u00e9pressifs dans le cadre d\u2019un trouble bipolaire, et priorit\u00e9 donn\u00e9e aux alternatives th\u00e9rapeutiques disponibles.<\/p>\n
Les prescripteurs sont invit\u00e9s \u00e0 recourir \u00e0 une alternative th\u00e9rapeutique lors de l\u2019initiation de traitement et, d\u00e9sormais, aussi pour les patients d\u00e9j\u00e0 trait\u00e9s, d\u00e8s que possible et pour toutes les indications, sauf en cas d\u2019\u00e9pisode d\u00e9pressif caract\u00e9ris\u00e9 dans le cadre d\u2019un trouble bipolaire. Les sp\u00e9cialit\u00e9s \u00e0 base de risp\u00e9ridone, de palip\u00e9ridone, d\u2019amisulpride et de d\u00e9riv\u00e9s du valproate (divalproate de sodium, valpromide), d\u00e9j\u00e0 en tension d\u2019approvisionnement, ne doivent pas \u00eatre utilis\u00e9es comme alternatives \u00e0 la qu\u00e9tiapine. L\u2019aripiprazole est cit\u00e9 comme alternative de premi\u00e8re intention. Ces mesures et recommandations rel\u00e8vent principalement de l\u2019ANSM et s\u2019inscrivent dans la r\u00e9gulation de l\u2019offre de soins, la s\u00e9curisation de la prise en charge des patients et la gestion des tensions d\u2019approvisionnement en m\u00e9dicaments en France.\u00a0(contenu r\u00e9sum\u00e9 par l’IA)Lire la Suite<\/a><\/p>","protected":false},"excerpt":{"rendered":" Un arr\u00eat\u00e9 du 17 juillet 2026 abroge, \u00e0 compter du 20 juillet 2026, l\u2019arr\u00eat\u00e9 du 12 f\u00e9vrier 2025 qui rendait obligatoire la d\u00e9livrance \u00e0 l\u2019unit\u00e9 des m\u00e9dicaments \u00e0 base de […]<\/p>\n","protected":false},"author":1,"featured_media":9774,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[7],"tags":[224,227],"class_list":["post-18228","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicaments-et-produits-de-sante","tag-omedit","tag-ia"],"_links":{"self":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/18228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18228"}],"version-history":[{"count":0,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/18228\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/media\/9774"}],"wp:attachment":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}